Advertisement

Drugs & Therapy Perspectives

, Volume 34, Issue 7, pp 289–299 | Cite as

Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

  • Katherine A. Lyseng-Williamson
  • Jürgen Behr
Adis Drug Q&A

Abstract

Ambrisentan [Volibris® (EU), Letairis® (USA)], an endothelin-1 receptor antagonist, is effective in treating WHO functional class (FC) II/III pulmonary arterial hypertension (PAH) when used as monotherapy or in combination with tadalafil (a phosphodiesterase type-5 inhibitor). In patients with idiopathic PAH or PAH associated with connective tissue diseases, ambrisentan monotherapy provided sustained clinical benefits, including improvements in exercise capacity. Clinical benefits, including a lower risk of clinical failure, were greater with initial combination treatment with ambrisentan + tadalafil than with initial monotherapy with either ambrisentan or tadalafil in patients with PAH, including those in various patient subgroups. Ambrisentan has an acceptable tolerability and safety profile with or without concomitant tadalafil. Based on the results of clinical trials, current guidelines recommend ambrisentan as initial mono- or combination treatment in patients with non-vasoreactive WHO FC class II/III PAH.

Notes

Acknowledgements

The manuscript was reviewed by: L. Sargento, Heart Failure Unit, Cardiology Department, Pulido Valente Hospital, Lisbon North Hospital Centre, Lisbon, Portugal; D. Skowasch, Department of Internal Medicine II, Division of Cardiology and Pneumology, University of Bonn, Bonn, Germany. During the peer review process, Glaxo Group Ltd, the marketing authorisation holder of ambrisentan, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. A. Lyseng-Williamson is a salaried employee of Adis/Springer and declares no conflict of interest. J. Behr declares having received payments for consulting and lecturing from Actelion, Bayer, Biogen, Boehringer-Ingelheim, Galapagos NV, Novartis and Roche, and having received a grant from Boehringer-Ingelheim.

References

  1. 1.
    Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;46(4):903–75.Google Scholar
  2. 2.
    Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):S40–7.CrossRefGoogle Scholar
  4. 4.
    Volibris (ambrisentan) 5 and 10 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency, 2017.Google Scholar
  5. 5.
    Safdar Z. Targeted oral therapies in the treatment of pulmonary arterial hypertension. Clin Drug Investig. 2010;30(12):811–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Croxtall JD, Lyseng-Williamson KA. Tadalafil in pulmonary arterial hypertension. Drugs. 2010;70(4):479–88.PubMedCrossRefGoogle Scholar
  7. 7.
    Talmaco (tadalafil) 20 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2017.Google Scholar
  8. 8.
    Liang F, Yang S, Yao L, et al. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries. Hypertension. 2012;59(3):705–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension. Chest. 2011;139(1):109–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Blalock SE, Matulevicius S, Mitchell LC, et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail. 2010;16(2):121–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Klinger JR, Oudiz RJ, Spence R, et al. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol. 2011;108(2):302–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Galiè N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Galiè N, Barberá JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192(9):1102–10.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    D’Alto M, Romeo E, Argiento P, et al. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertenison: cLinical and haemodYnamic long-term efficacy (ITALY study). J Cardiovasc Med. 2018;19(1):12–7.CrossRefGoogle Scholar
  17. 17.
    Vachiéry JL, Hoeper MM, Peacock AJ, et al. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: the VOLibris tracking study. J Heart Lung Transplant. 2017;36:399–406.PubMedCrossRefGoogle Scholar
  18. 18.
    Shapiro S, Torres F, Feldman J, et al. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Resp Med. 2017;126:84–92.CrossRefGoogle Scholar
  19. 19.
    Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(21):971–81.CrossRefGoogle Scholar
  20. 20.
    Oudiz R, Allard M, Blair C, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension: 3-year outcome [abstract plus poster no. 2622]. In: American College of Chest Physicians International Conference; 2011.Google Scholar
  21. 21.
    Pulido T. Long-term ambrisentan therapy for pulmonary arterial hypertension: comparison by etiology [abstract plus poster no. K89]. In: The American Thoracic Society International Conference; 2009.Google Scholar
  22. 22.
    Coghlan JG, Galiè N, Barberà JA, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76:1219–27.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Mclaughlin V, Galie N, Barbera JA, et al. A comparison of characteristics and outcomes of patients with atypical and classical pulmonary arterial hypertension from the AMBITION trial [abstract]. Am J Resp Crit Care Med. 2015;191(Abstr Suppl):A2196.Google Scholar
  24. 24.
    Hoeper MM, McLaughlin VV, Barberá JA, et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016;4:894–901.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhuang Y, Jiang B, Gao H, et al. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res. 2014;37(6):507–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Shapiro S, Pollock DM, Gillies H, et al. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol. 2012;110(9):1373–7.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Vizza CD, Fedele F, Pezzuto B, et al. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf. 2012;11(6):1003–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Badesch DB, Peschel T, Pizzuti D, et al. Post-marketing hepatic safety profile of ambrisentan in patients with pulmonary arterial hypertension: 4 year update [abstract no. 152]. In: 32nd annual meeting and scientific sessions of the International Society for Heart and Lung Transplantation; 2012.Google Scholar
  29. 29.
    Lepist E, Gillies H, Smith W, et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS One. 2014;9(1):e87548.  https://doi.org/10.1371/journal.pone.0087548.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135(1):122–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Spence R, Mandagere A, Richards DB, et al. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010;88(4):513–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Harrison B, Magee MH, Mandagere A, et al. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig. 2010;30(12):875–85.PubMedCrossRefGoogle Scholar
  33. 33.
    Spence R, Mandagere A, Dufton C, et al. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol. 2008;48(12):1451–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Spence R, Mandagere A, Harrison B, et al. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci. 2009;98(12):4962–74.PubMedCrossRefGoogle Scholar
  35. 35.
    Walker G, Mandagere A, Dufton C, et al. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol. 2009;67(5):527–34.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Sommer N, Grimminger J, Ghofrani HA, et al. Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. Pulm Pharmacol Ther. 2014;28(1):87–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Richards DB, Spence R, Mandagere A, et al. Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers. J Clin Pharmacol. 2011;51(1):102–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Gillies HC, Wang X, Staehr P, et al. Pah therapy in HIV: lack of drug-drug interactions between ambrisentan and ritonavir [abstract]. Am J Respir Crit Care Med. 2011;183:A5913.Google Scholar
  39. 39.
    Spence R, Mandagere A, Walker G, et al. Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. Clin Drug Investig. 2010;30(5):313–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Markert C, Hellwig R, Burhenne J, et al. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Eur J Clin Pharmacol. 2013;69(10):1785–93.PubMedCrossRefGoogle Scholar
  41. 41.
    Richards DB, Walker GA, Mandagere A, et al. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009;49(6):719–24.PubMedCrossRefGoogle Scholar
  42. 42.
    Mandagere A, Coar B, Bird SW, et al. Absence of a clinically relevant pharmacokinetic interaction between ambrisentan and mycophenolate mofetil [abstract]. Am J Respir Crit Care Med. 2010;181(Abstr Suppl):A3356.Google Scholar
  43. 43.
    Harrison B, Despain D, Mandagere A, et al. Omeprazole has no clinically relevant effect on the pharmacokinetics of ambrisentan [abstract]. Am J Respir Crit Care Med. 2009;179(Abstr Suppl):A3348.Google Scholar
  44. 44.
    Mandagere A, Coar B, Bird SW, et al. Steady state tacrolimus has no effect on the steady state pharmacokinetics of ambrisentan in healthy subjects [abstract]. Am J Respir Crit Care Med. 2010;181(Abstr Suppl):A3352.Google Scholar
  45. 45.
    Makert C, Kastner IM, Hellwig R, et al. The effect of induction of CYP3A4 by St John’s wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic Clin Pharmacol Toxicol. 2015;116(5):423–8.CrossRefGoogle Scholar
  46. 46.
    Markert C, Wirching T, Hellwig R, et al. Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. Int J Clin Pharmacol Ther. 2014;52(11):957–64.PubMedCrossRefGoogle Scholar
  47. 47.
    Venitz J, Zack J, Gillies H, et al. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012;52(12):1784–805.PubMedCrossRefGoogle Scholar
  48. 48.
    Ghofrani H-A, Schermuly R, Weissmann N, et al. Drug interactions in pulmonary arterial hypertension and their implications. US Cardiol. 2009;6(2):101–6.Google Scholar
  49. 49.
    Ciracì R, Tirone G, Scaglione F. The impact of drug-drug interactions on pulmonary arterial hypertension therapy. Pulm Pharmacol Ther. 2014;28(1):1–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Dingemanse J, Sidharta PN, Maddrey WC, et al. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014;13(3):391–405.PubMedCrossRefGoogle Scholar
  51. 51.
    Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012;30(2):93–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Maron BA, Waxman AB, Opotowsky AR, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol. 2013;112(5):720–5.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Bourge RC, Pamboukian SV, Tallaj JA, et al. The safely change from bosentan to ambrisentan in pulmonary hypertension (SCOBA-PH) study [abstract]. Am J Respir Crit Care Med. 2013;187:A3299.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand
  2. 2.Department of Internal Medicine V, Comprehensive Pneumology CentreUniversity of MunichMunichGermany

Personalised recommendations